Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095127 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
A Phase 2 study of Immune Thrombocytopenia (ITP), sponsored by Nuvig Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07095127 is a Phase 2 study of Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by Nuvig Therapeutics. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07095127, a Phase 2 study of Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by Nuvig Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Conditions Studied
Interventions
- DRUG NVG-2089
Study Locations (1)
New York
- Nuvig Site - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07095127
The ClinicalTrials.gov registry entry for NCT07095127 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuvig Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 1 intervention - of which NVG-2089 is the first listed.
NCT07095127 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07095127 about?
NCT07095127 is a clinical study titled "Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia". The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is d...
What is the current status of trial NCT07095127?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-30. Estimated completion is 2026-12-31.
What conditions does trial NCT07095127 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT07095127?
The interventions under investigation include: NVG-2089 (DRUG).
Who is sponsoring clinical trial NCT07095127?
This trial is sponsored by Nuvig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095127 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.